Onconetix (BWV) Stock Price, News & Analysis

Company Overview

Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Key Stats

• Today's Range: $76.89 to $77.50
• 50-Day Range: $0.18 to $0.18
• 52-Week Range: $0.18 to $1.95
• Volume: 1,999 shs
• Average Volume: 795,235 shs
• Market Capitalization: $1.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BWV Stock Analysis - Frequently Asked Questions

When did Onconetix IPO?

Onconetix (BWV) raised $20 million in an initial public offering (IPO) on Friday, February 18th 2022. The company issued 2,222,222 shares at $9.00 per share.

Company Calendar

• Today: 5/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BWV
• CIK: 1782107
• Web: www.bwbioinc.com
• Phone: 513-620-4101
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -108.19%
• Return on Assets: -66.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.54
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.63 per share
• Price / Book: 47.55

Miscellaneous

• Outstanding Shares: 18,660,000
• Free Float: 15,017,000
• Market Cap: $1.45 billion
• Optionable: Not Optionable
• Beta: 3.58